| Project/Area Number |
15K06854
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
Isono Takahiro 滋賀医科大学, 実験実習支援センター, 准教授 (20176259)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YUASA Takeshi 公益財団法人がん研究会, 有明病院 泌尿器科, 副部長 (00314162)
CYANO Tokuhiro 滋賀医科大学, 臨床検査医学, 准教授 (40346028)
KAGEYAMA Susumu 滋賀医科大学, 泌尿器科学, 講師 (50378452)
YOSHIDA Tetsuya 滋賀医科大学, 泌尿器科学, 助教 (60510310)
KAWAUCHI Akihiro 滋賀医科大学, 泌尿器科学, 教授 (90240952)
|
|---|
| Research Collaborator |
SUZAKI Masafumi
KITA Hiroko
KIMURA Fumiko
USHIO Akiyo
ISHIDA Syouhei
MAKINO Ai
YAMAMOTO Takefumi
URUSHIYAMA Noboru
MORI Yasuhiro
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | 腎癌 / 栄養枯渇耐性 / 遺伝子発現解析 / 予後予測マーカー / 新規分子標的 / ミトコンドリア / 活性酸素 / アポトーシス / 治療ターゲット / 治療薬ターゲット |
|---|
| Outline of Final Research Achievements |
This study analyzed the global transcriptional expression of deprivation-resistant and deprivation-sensitive renal cell carcinomas (RCC) cells and tissues of patients with RCC using a next generation sequencer to search for new biomarkers and therapeutic targets for RCC. Our analysis demonstrated that SOD2, HIF-2, TRAIL, ARL4C genes were useful for predict poorer prognosis in patients with RCC. And according to the results that therapeutic inhibition of mitochondrial function supported by SOD2 and metabolite stock induces cell death and HIF-2 and FLIP attenuated from TRAIL-induced apoptosis in starvation-resistant renal cell carcinomas, we demonstrated that buformin, a biguanide used in the treatment of diabetes mellitus, etomoxir, an inhibitor of beta-oxidation from fatty acids, and chetomin, a nuclear HIF-inhibitor, might be potential therapeutic drugs for RCC.
|
